To evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A
Phase 1 to evaluate the safety and pharmacokinetics drug-drug interaction of YYC506-T and YYC506-A. Which is designed as two cohort, single-sequence, paralle, open label, multiple oral dosing.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
ChungBuk National University Hospital
Cheongju-si, South Korea
Pharmacokietic parameters administration: Cmax
YYC506-T, YYC506-A, and concomitant administration Cmax
Time frame: Until 48 hours
Pharmacokietic parameters administration: AUC
YYC506-T, YYC506-A, and concomitant administration AUC
Time frame: Until 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
concomotant administration